4D Molecular Therapeutics, Inc.
NASDAQ:FDMTBiotechnology
+$0.16 today
- Market cap
- $577.85M
- Beta
- 2.76
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$2.36
Volume 0.68M
Average 0.77M
Balance Sheet
Inspect the capital base behind the business.
Assets
$566.71M
FY 2025 · Annual
+1.1% YoYLiabilities
$61.05M
FY 2025 · Annual
+22.6% YoYEquity
$505.66M
FY 2025 · Annual
-1.0% YoYBalance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 153M | 52.35M | 249.11M | 149.34M | 60.24M |
| Short-term Investments | 94.78M | 161.2M | 39.12M | 275.54M | 342.41M |
| Net Receivables | 47K | 700K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 8.46M | 6.26M | 8.36M | 10.06M | 10.48M |
| Total Current Assets | 256.28M | 220.51M | 296.59M | 434.93M | 413.13M |
| Property, Plant & Equipment (Net) | 28.95M | 35.35M | 31.67M | 40.61M | 33.01M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 67.65M | 4.91M | 10.95M | 80.58M | 111.38M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 602K | 1.08M | 684K | 4.26M | 9.19M |
| Total Non-current Assets | 97.21M | 41.34M | 43.3M | 125.45M | 153.58M |
| Total Assets | 353.49M | 261.85M | 339.89M | 560.38M | 566.71M |
| Account Payables | 4.76M | 3.32M | 3.52M | 4.39M | 11.16M |
| Short-term Debt | 0 | 2.66M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 2.6M | 884K | 273K | 257K | 360K |
| Other Current Liabilities | 0 | 3.18M | 3.87M | 0 | 0 |
| Total Current Liabilities | 16.34M | 15.73M | 18.95M | 29.15M | 43.99M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 2.49M | 1.08M | 972K | 1.06M | 745K |
| Other Non-current Liabilities | 334K | 233K | 617K | 603K | 496K |
| Total Non-current Liabilities | 18.04M | 14.78M | 13.11M | 20.63M | 17.06M |
| Total Liabilities | 34.38M | 30.51M | 32.06M | 49.78M | 61.05M |
| Common Stock | 3K | 3K | 4K | 5K | 6K |
| Retained Earnings | (207M) | (314.49M) | (415.33M) | (576.2M) | (716.3M) |
| Accumulated OCI | (423K) | (1.2M) | 16K | 229K | 727K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 319.11M | 231.34M | 307.83M | 510.61M | 505.66M |
| Total Debt | 16.45M | 16.12M | 14.67M | 24.61M | 21.41M |
| Net Debt | (136.55M) | (36.23M) | (234.44M) | (124.73M) | (38.83M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $72.5M |
| Short-term Investments | $318.4M |
| Other Current | $14.5M |
| Total Current Assets | $405.4M |
| PP&E (Net) | $30.9M |
| Long-term Investments | $66.7M |
| Other Non-current | $9.9M |
| Total Non-current Assets | $107.5M |
| Total Assets | $512.9M |
Analysis
Selected assets total $512.9M for Latest. The largest visible component is Short-term Investments at $318.4M, about 62.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 20, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 7, 2026 |
How much cash does FDMT have?
4D Molecular Therapeutics, Inc. (FDMT) reported $60.24M in cash and equivalents in fiscal 2025.
How much debt does FDMT carry?
4D Molecular Therapeutics, Inc. (FDMT) reported $21.41M of total debt, with net debt of -$38.83M.
Continue the stock analysis
Jump to another research area for this company.